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Nutrient Sensing by Histone Marks: Reading the Metabolic
Histone Code Using Tracing, Omics, and Modeling
Scott E. Campit, Alia Meliki, Neil A. Youngson, and Sriram Chandrasekaran*
Several metabolites serve as substrates for histone modifications and
communicate changes in the metabolic environment to the epigenome.
Technologies such as metabolomics and proteomics have allowed us to
reconstruct the interactions between metabolic pathways and histones. These
technologies have shed light on how nutrient availability can have a dramatic
effect on various histone modifications. This metabolism–epigenome cross
talk plays a fundamental role in development, immune function, and diseases
like cancer. Yet, major challenges remain in understanding the interactions
between cellular metabolism and the epigenome. How the levels and fluxes of
various metabolites impact epigenetic marks is still unclear. Discussed herein
are recent applications and the potential of systems biology methods such as
flux tracing and metabolic modeling to address these challenges and to
uncover new metabolic–epigenetic interactions. These systems approaches
can ultimately help elucidate how nutrients shape the epigenome of microbes
and mammalian cells.
1. Introduction
Histones are susceptible to a variety of post-translational modi-
fications (PTMs). These include acetylation, methylation, phos-
phorylation, ubiquitination, sumoylation, glycosylation, and
many others. These histone PTMs in combination serve as an
“epigenetic code” for transcriptional activation, repression, and
coordination of higher-order chromatin structure.[1–3]
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Histone PTMs are highly sensitive to
cellular metabolism (Figure 1).[2,4,5] Sev-
eral metabolites influence gene expression
by serving as substrates for modification
of histones or as regulators of epigenetic
enzymes.[4] The metabolite S-adenosyl me-
thionine (SAM) donates a methyl group
to methyltransferase enzymes for histone
methylation. Histone demethylating en-
zymes are dependent on intracellular lev-
els of Flavin adenine dinucleotide (FAD),
𝛼-ketoglutarate, iron, and oxygen. Acetyl-
CoA, an important biomolecule produced
from glucose, amino acid and fatty acid
catabolism, is the substrate for histone
acetyltransferase (HAT) enzymes, while
NAD+ (nicotinamide adenine dinucleotide)
is the substrate for sirtuins, a class of
deacetylase enzymes.
Histone PTMs thus represent an innate
cellular mechanism that links metabolic
status to gene expression. By sensing the
levels of intracellular metabolites, cells can alter the expression
of genes that are important for biological processes such as cell
growth and differentiation. Furthermore, as metabolism pro-
vides the building blocks for histone PTMs, in many cases, these
building blocks limit the creation of histone marks. For instance,
lack of dietary folate can lead to impaired histone methylation
during development.[4] Dysregulation of both metabolism and
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Figure 1. Interactions between metabolites and epigenetic enzymes impact the histone code. Cells normally utilize glucose (red) to synthesize the acety-
lation substrate acetyl-CoA. There are several nuclear metabolic enzymes that supply a local source of acetyl-CoA for histone acetylation, including PDH,
ACLY, and ACSS2. Acetyl-CoA in the nucleus is used by histone acetyltransferases (HAT) to modify lysine groups on histone tails. Sirtuins are histone
deacetylases (HDACs) that depend on local NAD+ to deacetylate histone tails. Histone methylation (blue) depends on one-carbon donors: methionine
and folate. The metabolic enzyme MAT in the cytosol and the nucleus, converts l-methionine to S-adenosylmethionine, the substrate for histone methy-
lation. Histone lysine methyltransferases (KMT) use SAM to methylate lysine groups on histone tails. Folate allows recycling of homocysteine (Hcy)
back to l-methionine to continue the production of SAM. Histone demethylases (KDMT) remove methyl groups using two distinct mechanisms. LSD
family demethylases act using a FAD-dependent amine oxidase reaction to demethylate histone lysine residues. JmjC domain family demethylases use
an 𝛼-ketoglutarate-Fe(II)-dependent dioxygenase reaction for demethylation.
the epigenome are important hallmarks of cancers andmetabolic
disorders such as diabetes, obesity, and hypertension.[2,4–6]
How histone PTMs sense and integrate various metabolic in-
puts is still unclear.[5] This has been challenging to investigate be-
cause histone PTMs sense several central metabolites that are in
turn involved in numerousmetabolic reactions.[5] Here, we high-
light recent technologies that can help us tackle the highly inter-
connected and compartmentalized nature of cellular metabolism
and its myriad impacts on the epigenome.
2. Metabolism–Histone Interactions Regulate
Normal and Disease Physiology
Metabolic–epigenetic interactions play a central role in devel-
opment and normal physiology of various organisms.[2] For
example, the interactions between histones and cellular metabo-
lites are important for controlling gene expression during the
cell cycle. The temporal peak in abundance of acetyl-CoA during
the yeast cell cycle correlates with histone acetylation of growth
genes.[7,8] Levels of histone glycosylation by acetylglucosamine
(GlcNAc) also changes during the cell cycle. Histone GlcNAcy-
lation depends on the activity of the hexosamine biosynthesis
pathway and is sensitive to the availability of glucose, fatty acids,
uridine, and glutamine; thus it may act as a nutrient sensor of
diverse metabolic pathways.[9,10] Metabolism and histone acety-
lation also play an important role in DNA repair in mammalian
cells. Upon DNA damage, nuclear ATP-citrate lyase (ACLY) pro-
motes acetyl-CoA production, facilitating histone acetylation at
the sites of double-strand breaks and stimulates DNA repair.[11]
Some cellular metabolites directly regulate the expression of
metabolic genes via histone modification. The FAD-dependent
enzyme LSD1 has been shown to demethylate histones and
regulate cellular energy levels by repressing genes involved in
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mitochondrial respiration and energy expenditure.[12,13] Another
example is found in brown adipose tissue development. Themas-
ter metabolic regulator—AMP-activated protein kinase (AMPK),
causes increased production of 𝛼-ketoglutarate, the substrate
for demethylases; 𝛼-ketoglutarate accumulation results in epige-
netic activation of adipogenesis regulators by demethylation of
their promoters.[14] In response to stress, AMPK also phospho-
rylates histone H2B serine residues (H2BS36) in mammalian
cells and regulates the activity of HATs and deacetylases through
phosphorylation.[15]
Metabolism-driven epigenetic changes can influence cancer
risk.[16] In mammalian cells, the set of genes activated by the
c-Myc oncoprotein[17] through metabolic rewiring and chro-
matin remodeling[18] resembles the set of growth genes that are
acetylated during acetyl-CoA peak abundance in the yeast cell
cycle.[2,7,8] Metabolic gene mutations in diverse cancers cause an
accumulation of succinate, fumarate, and R-2-hydroxyglutarate.
The accumulation of thesemetabolites is believed to contribute to
tumorigenesis by inhibiting 𝛼-ketoglutarate-dependent demethy-
lase enzymes including the tumor suppressor TET2.[2,19] Other
studies have shown the NAD-dependent deacetylase enzymes—
sirtuins, to be tumor suppressors, as they limit reactive oxygen
species (ROS) synthesis.[20,21] Low NAD levels results in de-
creased sirtuin activity and increased risk for many cancers,
likely due to DNA damage by ROS.[21,22] The enzyme nicoti-
namide N-methyltransferase (NNMT) is overexpressed in
numerous cancers. Increase in NNMT activity consumes SAM,
impairing histone methylation and leading to altered expression
of cancer-associated genes.[23]
Besides cancer, multiple studies have been conducted to better
understand the effect of epigenetic changes on disease pathology.
The level of H3K4 trimethylation, a histone mark associated with
active transcription, in the promoters of genes involved in lipid
metabolism, adipogenesis, and inflammation, correlates with in-
creasing BMI of individuals.[24] The availability of folate and other
one-carbon donors during conception and pregnancy influences
the epigenome and various phenotypes in offspring.[25] SAM and
methionine availability also plays an important role in mainte-
nance of pluripotency in stem cells. The depletion of SAM in
stem cells diminishesH3K4 trimethylation levels and leads to en-
hanced differentiation.[26,27] In summary, these examples provide
a connection between intracellular metabolites, histone marks
and their effect on gene transcription, which may contribute to
the progression of diseases.
3. Metabolic–Epigenetic Cross Talk Is Complex and
Context-Specific
The numerous metabolic pathways that intersect with histone
PTMs make it highly challenging to understand their interde-
pendencies. For example, acetylation is sensitive to acetyl-CoA
and NAD+,[2,4] which are involved in hundreds of metabolic re-
actions. Methylation depends on highly connected metabolic in-
termediates (𝛼-ketoglutarate, SAM) and redox factors (FAD), as
well.[2,4]
As with any other process in biology, the metabolic impact on
histone PTMs is context specific. For example, inhibiting the syn-
thesis of SAM, the substrate for methylation, reduces histone
methylation in primed murine embryonic stem cells.[28] How-
ever, the same inhibition does not alter bulk methylation in naïve
embryonic stem cells.[28] Another layer of complexity results
from extensive cross-talk between different histone PTMs with
some PTMs stimulating or repressing others.[29,30] For example,
H3K4methylation can stimulate an increase inH3K9 acetylation.
In contrast, butyrylation can preclude acetylation of the same
histone.[30,31] Thus, understanding how cellular metabolism in-
fluences histone PTMs is a significant challenge.
The histone PTM levels in a cell depend on the activity of both
PTM writers and erasers. The writers comprise enzymes such as
histone methyltransferases and HATs, while histone demethy-
lases and histone deacetylases are examples of “erasers.” The
availability of substrates and cofactors, such as folates, acetyl-
CoA, SAM, and 𝛼-Ketoglutarate, influences the activity of these
epigenetic enzymes (i.e., writers and erasers).[2,4–6,28] For exam-
ple, the levels of a single histone PTM—acetylation, depends
on the levels of its substrate acetyl-coA, 17 distinct acetyltrans-
ferases, 18 different deacetylases and their substrates such as
NAD, and the presence of other histone marks like methylation.
Hence, increased acetylation in a cell could occur due to either
high acetyl-coA production or due to reduced deacetylase activity
arising from a change in redox metabolism. Consequently, acety-
lation has been found to increase in both nutrient excess and star-
vation conditions.[32,33]
There are over 250 such epigenetic enzymes in humans with
both distinct and overlapping substrates and targets (i.e., histone
sites).[34] Some histone sites can even be non-enzymatically mod-
ified directly by metabolites.[4] Furthermore, the extent of sen-
sitivity to metabolism for different PTMs changes with respect
to their positions in the histone.[4,35–37] For example, acetylation
at H3K9, H3K27, and H3K56, but not at H3K14, H3K18, and
H3K23, have been found to be sensitive to acetate addition.[35]
Similarly acetylation at H3K9, H3K14, H3K18, H4K8, H4K12,
and H4K16 was most sensitive to glucose levels while other
sites did not change significantly.[36] Our understanding of
how histone PTMs are influenced by metabolism can benefit
from systems biology approaches that account for numerous
components.
4. How to Trace Metabolic Signals to the Nucleus
While there are numerous pathways that can theoretically synthe-
size specific epigenetic substrates, such as acetyl-CoA, stable iso-
tope tracing analysis can tell us which pathway predominates in a
given condition. Combining isotope-labeled metabolomics with
proteomics is a powerful approach for uncovering metabolic–
epigenetic interactions. For instance, treating cells with heavy
isotope labeled glucose or acetate followed by proteomics mea-
surement of histone PTMs can help identify which molecule and
metabolic pathway contributes more to histone PTM synthesis.
Further, measuring the incorporation of stable isotope labeled
glucose or other metabolites over time can track the dynamics of
PTMs and trace metabolic pathways that support the synthesis of
PTM substrates (Figure 2).
Recent studies have used isotope-labeled tracing to uncover
how different acetylation sites exhibit unique sensitivity and dy-
namics for different substrates.[35,36,38,39] This approach can also
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help determine the quantitative relationship between histone
marks and metabolite levels and fluxes. Cluntun et al. created
a tunable system to titrate glucose at various concentrations in
a human colon cancer cell line.[36] They performed kinetic flux
profiling experiments using 13C labeled glucose to manipulate
glycolytic flux. They found that this glucose titration leads to dif-
ferent histone acylation (multiple PTMs) patterns, in which dif-
ferent sites show differing degrees of sensitivity to glycolytic flux.
Similarly,Mentch et al. found a quantitative link betweenmethio-
nine levels and histoneH3 trimethylation.[37] They found that the
S-adenosyl methionine/S-adenosyl homocysteine (SAM/SAH)
ratio was predictive of the levels of histone methylation in re-
sponse to methionine restriction. While a severe reduction in
histone di- and trimethylation in response to depletion of SAM
or methionine has been observed in many systems,[23,26–28,37,40]
Haws et al. found that mammalian cells mount a highly coordi-
nated response to preserve H3K9 monomethylation.[41]
Tracing has also provided novel insights on how metabolic
pathways are rewired to impact histone PTMs in stem cells.
Chandrasekaran et al. traced 13C labeled glucose, glutamine,
and serine to show how carbon from glucose impacts histone
methylation during the naïve to primed transition in pluripotent
stem cells.[28] In these cells, glycolytic flux is routed toward the
one-carbon metabolic pathway, which influences serine and
folate metabolism, and leads to increased SAM synthesis and
ultimately histone methylation. Similarly, Moussaieff et al. used
labeled glucose tracing to uncover the impact of glycolytic flux
on acetyl-CoA synthesis and histone acetylation in naïve and
primed pluripotent stem cells.[42]
While glucose is considered the most common carbon source
for histone acetylation,[38,43,44] eukaryotic cells, especially cancer
cells, also utilize alternate carbon sources.[45] McDonnell et al.
combined 13C carbon tracing with acetyl-proteomics in immor-
talized hepatocytes (AML12 cells) to show that up to 90% of acety-
lation on histone lysines can be derived from fatty acid carbon
(octanoate), even in the presence of excess glucose.[46] A large
proportion of tumors also utilize carbon from acetate for histone
acetylation.[47] Using 13C labeling and multiple reactions moni-
toring mass spectrometry, Gao et al. found that during hypoxia,
acetate becomes a major carbon source for histone acetylation
in tumors.[35] Furthermore, carbons from branched-chain amino
acid oxidation is used to synthesize acetyl-CoA to support histone
acetylation in pancreatic acinar cells and contributes to the devel-
opment of pancreatic ductal adenocarcinoma.[48]
Flux tracing analyses have helped uncover how aberrant
metabolic rewiring can influence histone PTMs in tumors. Mor-
rish et al. used 13C glucose tracing to demonstrate that Myc over-
expression increases the mitochondrial synthesis of acetyl-CoA,
and a 40% increase in H4K16ac.[18] Cancer cells can channel car-
bon flux into acetyl-CoA to sustain high levels of histone acetyla-
tion even when glucose is limiting. This is achieved by increasing
the activity of ACLY or acetyl-CoA synthetase 2 (ACSS2) enzymes
that synthesize acetyl-CoA and support histone acetylation.[47] In
hypoxic tumors, acetate from histone deacetylation is recaptured
by nuclear ACSS2 and channeled for histone acetylation. ACSS2
helps maintain adequate nuclear acetyl-CoA levels to support hi-
stone acetylation even when there is high cytosolic demand for
acetyl-CoA to support lipogenesis.[44]
New histone marks have also been discovered using tracing
and mass spectrometry. For example, metabolic labeling us-
ing 13C l-lactate followed by mass-spectrometry analysis has
demonstrated that a novel histone mark—lysine lactylation,
can be derived from lactate.[49] Furthermore, metabolic labeling
experiments using isotopic glucose have demonstrated that
lysine lactylation is endogenously derived from glucose.
A limitation of these-isotope labeled tracing studies is that they
are done using bulk cellular measurements and as a result, sub-
cellular compartment information is lost. Acetyl-CoA and other
histone PTM substrates exist in distinct pools in mitochondria,
nucleus and other compartments.[50] Metabolite pools in the
mitochondriamay not have significant impact on histonemodifi-
cations in the nucleus. Recent studies have begun to address this
limitation through a variety of ways including fractionation to
separate organelles, compartment-specific chemical probes, and
via computational modeling. Lee et al. measured fluxes in mito-
chondria and cytosol by combining isotope tracing with subcellu-
lar fractionation and metabolomics.[51] However, the subcellular
fractionation process itself can lead to artifacts. Trefely et al. have
developed a post-labeling correction strategy to account for the
disruption caused by the fractionation of compartments.[52] Com-
putational models can also be used to deconvolute compartment-
specific metabolism from bulk measurements. Chandrasekaran
et al. were able to differentiate mitochondrial and cytosolic folate
metabolism from bulk metabolomics measurement using a
computational model of metabolism in various compartments,
and validated the model using chemical inhibitors that target
folate metabolism in distinct compartments.[28]
An essential requirement for isotope labeling experiments
is the steady-state labeling of metabolites, that is, the isotopic
labeling does not change over time. However, the exchange of
intracellular and external metabolites can significantly reduce
labeling rates and labeling may not reach steady state. For exam-
ple, cytosolic acetate freely exchanges with both acetyl-CoA and
extracellular acetate. This free exchange along with rapid protein
acetylation–deacetylation cycles can lead to labeling of histones
without a net carbon transfer. This makes it challenging to study
histone acetylation labeling by acetate. To overcome this, Bulusu
et al. utilized a chemical derivative of acetate to determine net
Figure 2. Flux tracing experiments and proteomic profiling under different conditions reveal the impact of metabolic rewiring on histone acetylation and
other histone PTMs. A) Histone acetylation labeling using 13C-labeled glucose and acetate. Measuring incorporation of the labeled acetyl group over
time using mass spectrometry enables quantification of histone acetylation dynamics and kinetic profiles of different histone writers and erasers. To
quantify the impact of metabolite concentrations on histone acetylation, metabolic flux analysis (MFA) can be used to infer intracellular fluxes for small
metabolic networks. The rate of labeling incorporation over time can be used to measure metabolic activity for various metabolic pathways. Combining
both proteomic kinetic profiling and MFA under different nutrient- and genetic perturbation conditions can reveal unique metabolic dependencies of
various histone PTMs. B) A schematic of a pulse-chase analysis to quantify histone acetylation/deacetylation rates from different nutrient sources. In a
pulse-chase experiment, an isotope tracer is introduced (pulse), and an unlabeled form of the nutrient replaces the tracer over time (chase). The time it
takes for the unlabeled acetyl groups to replace the labeled acetylated histones is the deacetylation rate for a given acetylation species.
BioEssays 2020, 42, 2000083 © 2020 Wiley Periodicals LLC2000083 (5 of 11)
www.advancedsciencenews.com www.bioessays-journal.com
acetate exchange rate and quantify labeling of histone-bound
acetate.[44]
Although isotope labeling patterns of metabolites can directly
provide qualitative information on relative pathway activities,
13Cmetabolic flux analysis (MFA)[53,54] can provide amore quan-
titative estimate of fluxes at key branch points. In MFA, label-
ing patterns of metabolites are used to computationally estimate
metabolic fluxes.[55] However, MFA is time-intensive and compu-
tational models with detailed atomicmapping are currently avail-
able only for a limited set of pathways in centralmetabolism.[53,54]
Finally, the interpretation of large numbers of metabolic
changes observed in tracing and metabolomics measurements
is a significant challenge.[56,57] While flux tracing is limited to a
small set of well-studied pathways, extensive metabolic changes
occur during differentiation or tumorigenesis resulting in altered
epigenetic modifications. Mechanistic modeling tools have now
been developed to interpret omics datasets. Recent studies have
also applied metabolic modeling methods to understand the in-
fluence of diverse metabolic changes on histone modifications.
5. Constraint-Based Modeling Can Predict and
Interpret Metabolism–Histone Cross Talk
All living cells contain numerous highly interconnected
metabolic pathways with varying degrees of activity. Tran-
scriptomics or metabolomics analysis can provide a snapshot of
cellular metabolism; however, transcript or metabolite changes
do not directly provide insights on the activity of various
metabolic reactions. For instance, increased accumulation of
tricarboxylic acid cycle (TCA cycle) metabolites may be due to
increased activity of glycolysis and TCA cycle or decreased activ-
ity of oxidative phosphorylation pathway. Similarly, changes in
mRNA levels of one pathway should be interpreted in the context
of all other pathways that are linked to it. Interpreting metabolic
changes through traditional informatics approaches such as
grouping genes into pathways is also challenging.[56] Usually,
individual proteins in a pathway do not change coherently as a
whole. Given the highly interconnected nature of the metabolic
network, the underlying assumption behind pathway analysis
that each predefined pathway is independent of each other does
not hold for metabolism as adjacent pathways can influence
each other’s activity. A systems-level model is needed to account
for changes at both the individual protein level and the overall
network level.
Metabolic network reconstructions address these challenges
and provide a virtual map of all known metabolic reactions that
happen in a human cell.[58] Metabolic network reconstructions
represent themechanistic relationships between genes, proteins,
and metabolites in a cell. For example, the human metabolic
model (Recon 2) contains 7440 reactions, 1789 genes, 2194 tran-
scripts, 2657 proteins, 1052 protein complexes, 8 cellular com-
partments, and 5063 metabolites.[59]
Several theoretical approaches that utilize metabolic
reconstructions to interpret transcriptomics[60–63] and
metabolomics[28,64,65] data have been developed. All these
approaches build upon a fundamental theoretical concept called
constraint-basedmodeling (CBM). CBM is a powerful theoretical
tool that is capable of simulating hundreds of enzymes in the
metabolic network.[66,67] Using CBM, we can identify an optimal
path through the network from nutrients to biomass compo-
nents based on thermodynamic, stoichiometric and enzyme
expression constraints. CBM does not require any kinetic pa-
rameters and can be used to simulate models with thousands of
reactions. Flux balance analysis, the oldest and most commonly
used CBM method, is formulated as an optimization problem,
wherein fluxes are estimated by assuming cellular metabolism
is optimized for the production of biomass components, subject
to stoichiometric constraints resulting from mass balances
for intracellular metabolites (Figure 3).[68] Further external
nutrient levels and metabolic secretion rates provide boundary
constraints on intracellular fluxes. Due to redundancies in the
metabolic network, additional constraints from transcriptomics
or metabolomics data are frequently used to limit the feasible
space of possible fluxes through the network.
CBM has been successfully used to predict the metabolic state
of various mammalian systems, including cancer cells and stem
cells.[28,60,69] CBM models have led to the discovery of biomark-
ers, metabolic vulnerabilities, and drug targets.[58,70] For exam-
ple, CBM identified dysregulation of mannose metabolism in
obese patients, which was validated by quantifying plasma man-
nose levels in lean and obese individuals.[71] Similarly, modeling
of hepatocyte metabolism revealed serine deficiency in patients
with non-alcoholic fatty liver disease.[72]
CBM is highly effective in predicting lethality of single and
combinatorial gene knockouts as this approach is good at predict-
ing infeasible metabolic states. For example, using a metabolic
model of renal-cell cancer cells, Frezza et al. discovered a syn-
thetic lethal interaction between the enzymes fumarate hydratase
(FH) and haem oxygenase.[73] Since FH mutations are common
in these cancers, haemoxidation could be targeted in tumorswith
FH inactivating mutations, while sparing normal cells with wild-
type FH. A metabolic model of hepatocellular carcinoma (HCC)
revealed that de novo lipogenesis is substantially upregulated in
patients with HCC and identified mitochondrial acetate as the
substrate for lipogenesis through the upregulation of mitochon-
drial acetyl-CoA synthetase 1 (ACSS1).[74]
Like all models, the accuracy of CBM depends on the avail-
ability of high-quality datasets to build and curate the metabolic
models. Further, the underlying assumptions of metabolic steady
state and optimization of biomass are not applicable for all sys-
tems. Nevertheless, these assumptions can be adjusted based on
experimental evidence. For example, time-course metabolomics
measurements can be used to identify metabolites that are not
at steady-state.[28,64] Similarly, complex objectives based on bio-
chemical tasks performed by a cell type such as neuron or hep-
atocyte can be used as an alternate optimization goal instead of
optimizing biomass.[59]
CBM methods have also been recently applied to gain insight
on how metabolic changes can influence histone modifications.
For example, a variation of CBM called dynamic flux activity
(DFA) uses snapshots of metabolite levels taken at different
time points and subsequently overlays this onto a metabolic
network model.[28] DFA was used to compare the metabolism
of embryonic- and induced-pluripotent stem cells using time-
course metabolomics of each cell state. DFA revealed the activa-
tion of the one-carbon metabolic pathway in mouse embryonic
stem cells transitioning from naïve to primed pluripotent state.
BioEssays 2020, 42, 2000083 © 2020 Wiley Periodicals LLC2000083 (6 of 11)
www.advancedsciencenews.com www.bioessays-journal.com
Figure 3. Using constraint-basedmodeling (CBM) to computemetabolic fluxes through themetabolic network. Genome-scale metabolic network recon-
structions map all known gene–protein-reaction associations using an iterative process of literature curation, database mining, and model refinement.
The resulting metabolic network is converted to a mathematical form as a matrix of the stoichiometries (S) for every single reaction–metabolite pair.
The product of the stoichiometric matrix (S) and the desired vector of metabolic fluxes going through each reaction (v) is equal to the rate of change
of metabolites (b). If b is set to 0, this represents quasisteady state conditions. Solving for v provides steady-state fluxes from the metabolic recon-
struction. To get a unique biologically feasible flux distribution, several constraints must be imposed on the model. A cellular objective is set, where a
cell is assumed to fulfill a specific metabolic task such as maximizing biomass production. Further, the structure of the metabolic network itself (S),
given that each reaction is mass- and charge-balanced, provides another constraint. Thermodynamic parameters such as Gibbs free energy can be used
to set reaction directions. Finally, datasets such as transcriptomics, proteomics, and metabolomics can be used to limit enzyme activity, flux bounds,
and substrate uptake rates. Together, these constraints can produce condition-specific metabolic profiles. Extending the metabolic network to include
reactions required for histone PTMs can simulate metabolomic–epigenomic interactions at the genome scale.
This activation enhances the synthesis of SAM and supports ex-
tensive histone methylation in primed stem cells. Inhibiting this
pathway reduced histone methylation in primed cells but not in
naïve cells, as predicted by the model. DFA also uncovered differ-
ences in folate metabolism between mitochondria and cytosol,
which is usually lost during bulk metabolomics measurement.
These predictions were then experimentally confirmed using
inhibition of folate enzymes in different compartments.
Notably, a new computationalmodel based onCBM for directly
simulating the dynamics of histone acetylation was recently de-
veloped by Shen et al.[32] This enabled them to predict the impact
of metabolic alterations on histone acetylation (Figure 3). To sim-
ulate acetylation using the metabolic network model, the authors
added biochemical reactions corresponding to histone acetyla-
tion and synthesis of acetyl-CoA in the nucleus.[43] This model
enabled them to correctly predict the histone acetylation levels of
various cell lines based on their metabolic activity, suggesting a
quantitative relationship between the two processes. This model
suggests that excess carbon that is not used for biomass synthesis
supports acetylation. It also explains why acetylation can increase
in certain nutrient stress conditions such as nitrogen starvation
that result in excess carbon levels. Finally, it also revealed that the
diversion of carbon flux for histone acetylation will have limited
impact on overall metabolism in an actively dividing cell. This is
significant given that histone acetylation accounts for 74% of all
acetylated lysines in mammalian cells.[75]
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CBM of metabolism–epigenome interactions is still in its
infancy. Existing models cannot yet differentiate between spe-
cific histone sites (e.g., H3K9 or H3K27). Further, CBM in
general cannot model the feedback regulation of metabolism
by transcriptional regulation induced by metabolic changes.
New approaches are being developed to model this feedback in
microbes,[62,76] andmay soon be able to tackle the regulatory com-
plexity in mammalian cells.
6. Next-Generation Technologies for Discovering
New Metabolic–Epigenetic Interactions
The development of new imaging, omics, and modeling tech-
nologies can help discover new interactions between these
two central cellular processes in the future. Ultimately, these
technologies together may make it possible to track a labeled
metabolite in a live cell, watch its transition between cellular
compartments and ultimately identify which histone modifica-
tion it ends up in at which gene.
A major influence in this area of research was the surprising
discovery that key mitochondrial energy metabolism enzymes
are present in the nucleus and provide metabolites for histone
modification.[77,78] These observations support the possibility that
other metabolic enzymes, which are primarily thought to func-
tion in the mitochondria or the cytoplasm, may directly facilitate
epigenetic change in the nucleus. Imaging techniques and sen-
sors to locate enzymes and metabolites in space are likely to be
powerful tools in this hunt.
A limitation of metabolomics and tracing approaches is that
they lack spatial resolution within a compartment like nu-
cleus. Many metabolic substrates are synthesized in the nucleus
and metabolism-driven epigenetic alterations may happen in
specific regions of the chromatin. Histone modifications may
change spatially at different loci even though the bulk levels
may remain the same. Next-generation sequencing approaches
such as chromatin-immunoprecipitation and sequencing (ChIP-
seq) allow identification of gene-specific epigenetic effects of
metabolism. Notably, Aranda et al. recently developed a DNA-
mediated chromatin pull-down technology to identify chromatin-
bound proteins in pluripotent stem cells.[79] Using this approach,
they discovered that the enzyme adenosyl-homocysteinase influ-
ences SAM/SAH ratio, thereby affecting methylation in chro-
matin subcompartments. Linking spatial metabolite levels cou-
pled with genome-wide and spatial measurements of histone
marks using ChIP-seq or chromatin capture technologies[80] will
enable the characterization of these local effects.
The advent of machine-learning algorithms has revolution-
ized many areas of biology.[81] Unlike traditional biochemical
modeling approaches, machine-learning algorithms can learn
patterns in data without relying on prior knowledge. In con-
trast, the mechanistic models (CBMs) employed in studies high-
lighted above were built using biochemical data on enzymes and
substrates curated from literature.[32] Using advanced machine-
learning algorithms like Deep learning may soon make it pos-
sible to directly predict histone modifications and ramifications
of metabolic alterations on the epigenome without knowledge
of underlying mechanism. While mechanistic modeling is lim-
ited to known reactions or interactions in literature, machine-
learning algorithms are ideally suited for uncovering novel inter-
actions. However, machine-learning algorithms are data-driven.
Hybrid approaches that integrate machine-learning and mecha-
nistic modeling[82,83] can enable us to effectively harness large-
scale metabolic and epigenomic datasets in the future.
7. Future Directions for Metabolism–Epigenetics
Research
Technological advances described above will reveal important
metabolic–epigenetic interactions in diverse areas of biology, as
well as opening up new research areas, and breathing life into
old biological puzzles. They can provide insights on the impact
of the tissue microenvironment on the epigenome during tu-
morigenesis, development, or ageing. Identification of unique
growth requirements of stem cells based on their epigenetic state
to improve their viability in culture can transform regenerative
medicine applications such as disease modeling and stem-cell
therapy.[84] Recent discoveries in neuroscience on the importance
of metabolism and epigenetics for memory and behavior[85–89]
and altered brain energy metabolism in conditions such as
obesity and aging[90,91] could underlie known associations be-
tween diet and the brain.[92] Another area that links metabolism
and epigenetics is transgenerational epigenetic inheritance. Re-
search has now confirmed that environmental exposures (e.g.,
diet, stress, toxins) can alter the phenotypes of future genera-
tions without altering DNA sequences.[93,94] In some cases, these
changes appear to provide amechanismof short-term adaption to
the exposure, which contrasts with the slower evolutionary pro-
cess of natural selection.[95,96] Numerous cases of transgenera-
tional epigenetic inheritance in rodents,C. elegans andDrosophila
stimulated by nutritional exposures suggests that metabolism–
epigenetic interactions may be part of these inheritance mecha-
nisms. Future work will reveal how widespread and important
these mechanisms are for adaptation in all species, including
our own.
The growth of metabolism–epigenetic research will bring
translational benefits through modulation of physiology for ther-
apy and agriculture. Manipulation of metabolism–epigenetic
mechanisms is a consequence of the ketogenic diet, a treatment
for epilepsy and some current cancer therapies.[97,98] Considering
the recently discovered importance of metabolism–epigenetic
regulation of immune cell development[99] it is likely that thera-
pies targeting those mechanisms will be developed for a variety
of inflammatory and infectious diseases. Understanding the
interdependencies of metabolic epigenetic processes can iden-
tify synergistic and antagonistic combinations of epigenetic and
metabolic inhibitors. Epigenetic drugs such as histone deacety-
lase inhibitors are being explored for treating immunological,
oncological, and neurological disorders.[100] Similarly, an-
timetabolites such as methotrexate, gemcitabine, and nucleotide
analogs are widely used for cancer therapy.[101] Thus, identifying
synergistic combinations of antimetabolites with epigenetic
inhibitors can enhance the efficacy of current therapies.[102]
Finally, as more is learned about how metabolism–epigenetic
interactions influence growth, health, and inheritance, there
could be improvements in animal production and crop yields
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through nutritional supplementation at multiple stages of the
life cycle or even multigenerationally.[103]
8. Conclusion
Regulation of gene expression through epigenetic chemical mod-
ifications is highly responsive to various metabolic cues. Mass
spectrometry-based proteomics and metabolomics technologies
are helping us uncover these interactions between metabolism
and the epigenome. Yet interpreting these vast datasets to under-
stand the interdependencies between these processes is challeng-
ing. Building virtual biochemical models represents an impor-
tant and timely opportunity to harness the vast amounts of omics
data and gain a better understanding of interactionmechanisms.
Further, it is likely that we have only scratched the surface on
the interplay between these two central cellular processes. Com-
bining cutting-edge tools from systems biology, imaging, mass
spectrometry, and artificial intelligence can ultimately uncover
interactions betweenmetabolism, histonemarks, and gene regu-
lation that underlie numerous biological processes and diseases.
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